anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A management system is used for management of patients on waiting lists in such fields as elective surgery, diagnostic services, clinic services and endoscopies. The system also administers administrative entities based on aggregate data provided by the system. The system has data entry, list management, audit and reporting functions. It acquires and creates its data. It calculates much data dynamically (in real time). For example, it stores data on when a patient entered onto a waiting list, and a patient's urgency score. Based on the urgency score, it calculates a target date for the patient. It dynamically (in real time) calculates the number of days a patient is from the target date, and ranks the patients accordingly. It filters a list of patients awaiting procedures according to various resource criteria. It provides for and manages referrals between systems, and lists, in different fields, and it allows calendar booking.
1. Technical Result Increase in efficiency of treating conditions caused by cyclooxygenase-2.         2. Essence Pyrazoline derivatives having the general formula wherein R1-R8 have the values indicated in the description; the use of the mentioned compounds and their physiologically acceptable salts can be used in the pharmaceutical industry as intermediates and for the preparation of medicaments; the pharmaceutical compositions containing the mentioned compounds can be used for the treatment of conditions mediated by cyclooxygenase-2, in particular inflammation including arthritis, fever, etc.; pyrazoline derivatives of the general formula (1) are obtained by interaction of compounds of formula (II) with phenylhydrazine of formula (II), the values of which are provided in the description and also by other alternative methods.          3. Field of Application Medicine.                         Tables: 7
All patients receive the same treatment of MAb-425 +Iodine 125 in a total of three injections. The purpose of this protocol is to allow you to receive course(s) of 1251-MAB 425 until your brain tumor begins to grow, you develop side effects to the treatment, or your medical condition changes (ie: become affected with human immunodeficiency virus (HIV) or develop another cancer).
Cancer-related cognitive impairment (CRCI) is a consequence of chemotherapy and extracranial radiation therapy (ECRT). Our prior work demonstrated gliosis in the brain following ECRT in SKH1 mice. The signals that induce gliosis were unclear. Right hindlimb skin from SKH1 mice was treated with 20 Gy or 30 Gy to induce subclinical or clinical dermatitis, respectively. Mice were euthanized at 6 h, 24 h, 5 days, 12 days, and 25 days post irradiation, and the brain, thoracic spinal cord, and skin were collected. The brains were harvested for spatial proteomics, immunohistochemistry, Nanostring nCounter® glial profiling, and neuroinflammation gene panels. The thoracic spinal cords were evaluated by immunohistochemistry. Radiation injury to the skin was evaluated by histology. The genes associated with neurotransmission, glial cell activation, innate immune signaling, cell signal transduction, and cancer were differentially expressed in the brains from mice treated with ECRT compared to the controls. Dose-dependent increases in neuroinflammatory-associated and neurodegenerative-disease-associated proteins were measured in the brains from ECRT-treated mice. Histologic changes in the ECRT-treated mice included acute dermatitis within the irradiated skin of the hindlimb and astrocyte activation within the thoracic spinal cord. Collectively, these findings highlight indirect neuronal transmission and glial cell activation in the pathogenesis of ECRT-related CRCI, providing possible signaling pathways for mitigation strategies.
Inflammation plays a key role in both the onset and progression of various kidney diseases. However, the specific molecular and cellular mechanisms by which inflammation drives kidney diseases from different etiologies remain to be elucidated. To enhance our understanding of these mechanisms, a reliable and translational human model of renal inflammation is needed. Here, we aim to establish such a model using human precision-cut kidney slices (PCKS). The PCKS were prepared from fresh, macroscopically healthy kidney tissue and cultured for 3h-48h with or without tumor necrosis factor-α (TNFα), or its inhibitor Etanercept. The ensuing inflammatory response in the slices was evaluated using both qPCR and a cytokine array. Furthermore, the presence of immune cells was visualized using immunofluorescent staining, and the activation potential of tissue-resident macrophages was examined with ELISA. We observed a culture-induced inflammatory response, reflected by increased expression of pro-inflammatory genes TNF, IL1B, CCL2, and IL6. This response could be partially inhibited by Etanercept, indicating that TNFα plays a role in the observed response. Moreover, we found that TNFα stimulation further increased the gene expression of TNF, IL1B, CCL2, and IL6, as well as the production of several chemokines and cytokines, including CXCL5, MCP1, MCP3, and IL-6. Lastly, we observed the presence of CD14- and HLA-DR-positive cells, as well as proliferating (CD68- and PCNA-positive) and activated macrophages in the slices during incubation. In conclusion, this study presents a novel human model for investigating renal inflammation.
This study is an open-label assessment of the feasibility of treating adolescents with psychotic disorders (schizophreniform disorder, schizoaffective disorder, psychosis not otherwise specified \[NOS\], major depressive disorder with psychotic features, and bipolar disorder with psychotic features) in an inpatient and day hospital setting with ziprasidone (Geodon). Ziprasidone is a second-generation antipsychotic (SGA) that is FDA-approved for the treatment of schizophrenia and for the treatment of the manic phase of bipolar disorder in adults. It is also used clinically in the treatment of psychotic disorders in children, adolescents and adults. This protocol will help to elucidate the feasibility of studying the treatment of psychotic disorders with ziprasidone in adolescents 13-17 years and help facilitate the further study of the treatment of psychosis with novel agents that have a favorable side effect and weight gain profile.

The duration of the study can be up to 7 weeks. Depending on the level of symptom severity patients will be managed on either the Schizophrenia Research Unit (SRU) (GAS\<35, CGI-S\>5), or the Children's Day Unit (CDU) of the NYSPI. The seven weeks would encompass a 3 day period at the beginning of the study including time for screening and reviewing lab results. Over a period of one to two weeks patients will be titrated up to 120 mg/day (80 mg for patients under 45kg), and, if necessary, cross tapered off of another SGA that had not been working successfully. Subjects who do not respond to the medication after 1 week at the target dose will be discontinued from the study.
Embodiments generally relate to a surgical resource allocation system. Patients seeking a procedure can use the system to identify surgeons and surgical facilities. The patient can then use the system to book the procedure with a selected surgeon at a selected facility. In an example, a patient can indicate a need for a certain procedure. The patient can then provide criteria for a surgeon or facility, such as a desired location, desired time, surgeon rankings, and facility rankings. The system can then identify surgeons and facilities that match the criteria and present them for selection by the patient. The patient can then select the surgeon and facility with which the patient would like the procedure performed. With the surgeon and facility selected, the patient can then choose to book the procedure.
1405108 Microcapsules AGFA-GEVAERT 11 Dec 1972 [23 Dec 1971] 59995/71 Heading B8C Microcapsules are prepared by emulsifying an aqueous fill material in a solution of a waterinsoluble film-forming material in a waterimmiscible solvent and rapidly adding further aqueous material so as to form a water (oil) water type emulsion, the quantities of liquids being chosen so that the volume of the first aqueous phase is not greater than that corresponding to the 1st insertion point of the system and the volumes of the first and second aqueous phases together are substantially equal to or higher than that corresponding to the second inversion point of the system. Thereafter the solvent is removed by evaporation (usually with continuous stirring), thereby forming the miorocapsules, which may be hardened &c. in conventional manner. Numerous suitable film-forming materials are mentioned which are addition polymers and copolymers, condensation polymers or modified natural polymers, e.g. vinyl polymers, acrylics, polyamides, polyesters, polycarbonates, poly-sulphonates, polyphosphonates, polyurethanes and cellulose derivatives. The core material may likewise be selected from a wide field of substances which are conventionally microencapsulated, particular reference being made to photographic chemicals such as gelatin silver halides, dyes, colour formers, colour reactants, development activators and retarders and bleaches. The aqueous phases may be the same or different, and the viscosity of the first aqueous phase may be increased by addition of suitable materials.
PCT No. PCT/US89/00788 Sec. 371 Date Apr. 7, 1989 Sec. 102(e) Date Apr. 7, 1989 PCT Filed Feb. 22, 1989 PCT Pub. No. WO89/08444 PCT Pub. Date Sep. 21, 1989.An improved skin cleansing-conditioning bar consisting essentially of, by weight, 8% to 38% of an anionic surfactant material selected from the group consisting of a sodium or potassium salt of a C-12-C-18 saturated monocarboxylic acid, a water-soluble, non-soap, anionic detergent selected from the group consisting of sodium and potassium salts higher acyl isethionates, higher alkyl sulfates, higher alkyl sulfonates, higher alkyl monoglyceride sulfates, higher alkylbenzene sulfonates, higher alkyl ethenoxy ether sulfates and mixtures thereof and mixtures of said monocarboxylic acid salt and said anionic detergent in a weight ratio of said monocarboxylic acid salt to said detergent of 18:1 to about 2.5:1; about 12% to 72% of a water-insoluble emollient selected from the group consisting of a C-14-C-18 alkanol and mixtures of said alkanol with a C-14-C-18 alkanoic acid wherein the weight ratio of alkanol to alkanoic acid is in the range of about 23:1 to about 0.6:1; the weight ratio of emollient material to said surfactant material being from about 10:1 to about 1.3:1; 0% to 60% of a starch-derived filler; and 2% to 12% of water; said bar having a pH in the range of 6 to 9.5 measured as a 1% by weight aqueous solution and yielding a satisfactory volume of a non-foaming, cleansing-conditioning cream of moderate viscosity when the wetted bar is rotated and manipulated between the wetted hands of the user. Included in the invention is the method of cleansing and conditioning the skin comprising the steps of forming a cream by rotating and manipulating the inventive bar between the wetted hands, applying the cream to the skin, massaging the cream into the skin and rinsing the cream-treated skin with water.
A frozen ice pack at -10 °C will be prepared for the patients in the experimental group. With these ice packs, the JP will be cooled to 13.6 °C, taking into account the literature, in order to create a local anesthetic effect on the drain outlet area before the drain is removed. Skin temperature will be measured intermittently with an infrared thermometer. When the skin temperature reaches 13.6 °C, the doctor will be informed and the drain will be removed. Before starting the cold application, immediately after the drain is removed, and after 15 minutes, considering the literature, pain will be measured with the "Visual Analog Scale". By ensuring that the drain removal procedure is performed by the same physician, individual differences that may arise will be prevented.
Hepatic encephalopathy, characterized by mental status changes and neuropsychiatric impairment, is associated with chronic liver disease as well as acute liver failure. In children, its clinical manifestations can be challenging to pinpoint. However, careful assessment for the development of hepatic encephalopathy is imperative when caring for these patients as progression of symptoms can indicate impending cerebral edema and systemic deterioration. Hepatic encephalopathy can present with hyperammonemia, but it is important to note that the degree of hyperammonemia is not indicative of severity of clinical manifestations. Newer forms of assessment are undergoing further research, and include imaging, EEG and neurobiomarkers. Mainstay of treatment currently includes management of underlying cause of liver disease, as well as reduction of hyperammonemia with either enteral medications such as lactulose and rifaximin, or even with extracorporeal liver support modalities.
Research suggests that combining therapies could result in important gains in restoring function and improving quality of life in persons with spinal cord injury (SCI). Locomotor training is an activity-dependent rehabilitation therapy that provides repetitive stepping facilitated by manual assistance and body weight support on a treadmill. Recent studies report improvements in walking and standing in individuals with motor incomplete SCI that have undergone intensive standardized locomotor training therapy. Extended release dalfampridine (also known as fampridine or 4-aminopyridine \[4-AP\]) is a broad spectrum potassium channel blocker that has been shown in animal studies to increase conduction of action potentials in demyelinated axons. Dalfampridine was recently approved by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in persons with multiple sclerosis (MS). Demyelination is also a prominent feature of incomplete SCI that contributes to the clinical presentation of persons with these injuries.

The purpose of this study is to determine the efficacy, safety, and tolerability of treatment with dalfampridine in combination with locomotor training in persons with chronic, motor incomplete SCI. We hypothesize that persons undergoing combination therapy with dalfampridine and locomotor training will show significantly greater improvements in walking speed and other measures of SCI function than those receiving locomotor training alone.
The present application relates, in part, to using vessel data to determine stent deployment locations and other parameters. Stent deployment may be planned such that the amount of blood flow restored by the stent is increased by one or more metrics relative to a vessel without the stent. An end user may specify one or more stent lengths, including a range of stent lengths. In turn, the diagnostic tool may generate candidate virtual stents having lengths within a specified range that are suitable for placement relative to the vessel representation. The vessel distance value, such as vessel diameter, radius, area, chord value or other cross-sectional area, etc., is used to identify the stent landing zone. These tools may use or supplement angiographic data and/or register with each other. The vessel data may be generated using optical imaging, ultrasound, angiography, or other imaging modalities.
Chronic pain remains a serious public health problem, resulting in approximately 100 million chronic pain patients in the U.S. alone \[1\]. While numerous treatments exist, none completely addresses this issue. In particular, spinal cord stimulation (SCS) has become an established technique for treating patients with chronic neuropathic pain \[2\]. The conventional paradigm for SCS treatment is to attempt to mask the pain by substituting the pain sensation with paresthesias \[3\]; however, newer studies have shown that it is possible to gain excellent pain relief without concomitant paresthesias ("sub-threshold stimulation") using different stimulation parameters \[4\] \[5\]. Because these paresthesia-free programming paradigms are still new, the best to place the stimulation and the best programming parameters to use is still unclear, making it difficult to place the leads during surgical implantation and to program the patient afterwards. Additionally, sub-threshold stimulation does not provide immediate pain relief, but may take several hours or even days to feel relief, making a simple programming session of a few hours insufficient to determine the optimal stimulation placement. While these differences from conventional SCS make programming more difficult initially, studying this new stimulation paradigm, especially differences in optimal stimulation location and the time course of pain relief, may also provide insight into the mechanism of action of sub-threshold stimulation. This protocol aims to study the optimal stimulation parameters and locations with SCS using sub-threshold stimulation.
INTRODUCTION: Human papillomavirus (HPV) is an epidemic currently affecting 80 million people in the United States. The HPV virus can be passed from one person to another via sexual intercourse, oral sex, open mouth kissing and skin-to-skin contact. In some cases, the infection is not eliminated by the immune system and can cause cancer of the head and neck, cervix, anus, and genitals. There has been a rise in oropharyngeal cancer (OPC) associated with HPV, which can be missed on conventional dental screening examinations. Dentists should engage in promoting HPV vaccination as a primary measure for OPC prevention. The goal of this HPV pilot program was to educate and offer same day HPV vaccination to dental patients by using a multidisciplinary approach in a hospital setting.
METHODS: Patients 18 through 26 years of age who presented to the Erie County Medical Center's dental clinic were approached and educated on HPV. Eligible patients received a direct recommendation for the HPV vaccine. Those interested in same day vaccination were referred to the division of infectious diseases' YOU Center for Wellness. A retrospective chart review was completed for patients who were HPV educated from March 5, 2020, through December 15, 2021. Charts were evaluated for age, sex, race, ethnicity, reason for visit, HPV vaccine referral, and HPV vaccine administration.
RESULTS: 326 patients were included in the chart review. The prominent sex, race, and ethnicity were male, Black or African American, and non-Hispanic origin. The median age was 23. Most patients presented to the dental clinic for an emergency visit and were not previously vaccinated against HPV. 110 patients were unvaccinated, and 44 patients were referred to the division of infectious disease for same day vaccination. Of these 44, 24 patients initiated the vaccination process. Five patients received all three doses, three patients received two doses, and 16 patients received one dose.
CONCLUSION: This pilot program successfully vaccinated 24 patients with at least a single dose of the HPV vaccine. This multidisciplinary model can be implemented in other health care settings.
PURPOSE:The titled composition, containing vitamin A, an antioxidant, e.g. di- tert-butylhydroxytoluene, butylhydroxyanisole or tocopherol, and EDTA salt, and having a stabilizing effect on the vitamin A for a long term. CONSTITUTION:An emulsion skin external agent composition containing vitamin A, 0.001-0.5%, based on the total composition, antioxidant, e.g. di-tert-butylhydroxytoluene, butylhydroxyanisole or tocopherol, and 0.001-0.5% EDTA salt as an emulsion medicinal pharmaceutical, quasi-drug or cosmetic, e.g. an emulsion, cream, aerosol or pack. The use of the specific antioxidant and EDTA salt improves the stability of the vitamin A remarkably without causing the problem such as the coloring of the system. 0.01-0.5%, based on the total composition, vitamin A palmitate or acetate is used as the vitamin A.
A clinical practice guideline (CPG) from the American Society of Plastic Surgeons recommended not to use drains in breast reduction. This CPG was based on 3 randomized controlled trials (RCTs). The objective of this review was to double-check the methodological quality of the 3 RCTs. These RCTs were critically appraised using: (1) the "User's Guide to the Surgical Literature" checklist to critically appraise the methodological quality, (2) the CONSORT guidelines for reporting quality, and (3) the Cochrane risk-of-bias tool 2 (RoB 2) for risk of bias. Weaknesses were identified in all assessments for the 3 RCTs. Items with the poorest adherence in the "User's Guide" included: "Were patients stratified?," "Was follow-up complete?," and "Were all clinically important outcomes considered?" The overall adherence to the CONSORT reporting checklist across all 3 studies was moderate with 40.0%, 62.1%, and 48.3% adherence. All 3 RCTs had a similar low to moderate risk of bias, with no areas with a high risk of bias. None of the studies took into consideration a single critical outcome (such as major hematoma) and the outcome's minimally important difference as the basis for the sample size and power calculation of the study. All 3 RCTs additionally lacked clear reporting of treatment effect sizes or precision of estimates. Our re-examination of the evidence questions the recommendation of the CPG. We believe that the recommendation should have been: "We remain uncertain whether drains in breast reduction have a salutary effect." As such, we recommend that a methodologically robust RCT be conducted to resolve the question of whether drains should be used in breast reduction.
One aspect of the invention is a method of controlling target living species with an active ingredient over an extended period of time. This method sorbs an active ingredient into colloidal clay. Next, a polymer pellet recalcitrant to release of the active ingredient is loaded with the sorbed colloidal clay. Finally, the loaded polymer pellet is formed into a barrier, which is adapted to be placed at a location for controlling a target living species. Another aspect is a barrier for controlling a target living species. The formed barrier contains polymer pellets loaded with colloidal clay sorbed with an active ingredient that controls the target living species. The sorbed clay loaded polymer pellets are recalcitrant to release of the active ingredient.
HAART in pregnant HIV-infected serves two goals, preventing mother to child transmission and providing adequate treatment for the mother. Levels of HIV RNA at delivery and the use of antiretrovirals (ARV) are independently associated with decreased transmission\[1\]. With a HAART regimen the transmission rate can be reduced till under the 2 %\[1, 2\]. Possibly suitable drugs which can be used during pregnancy is lopinavir/ritonavir based regimens. In Thailand, aluvir is not available therefore a generic lopinavir/ritonavir tablet formulation will be used in our study.

In order to prove adequate levels of lopinavir/ritonavir, we will record 12-hour PK at third trimester. Second trimester and post-partum 12-hour PK are optional. Furthermore, we will collect safety and efficacy throughout the study.
Participants assigned to the interoceptive exposure condition will receive twice-weekly 90-minute in-person treatment sessions for four weeks. This treatment will include education about anxiety and factors that maintain anxiety symptoms. In addition, participants will be asked to perform exercises designed to activate potentially distressing - but harmless - bodily sensations that are commonly associated with stress and anxiety. Participants will also be encouraged to practice these exercises daily at home.
Patients will receive Hormone therapy with at least one LHRH agent (Leuprolide Acetate or Goserelin) for 6 weeks and include bicalutamide. Patients will begin AT101 daily at 6 weeks for 3 weeks of every 4 weeks (4 weeks - 1 cycle) and continue for 8 cycles of combined therapy (combined AT101, and LHRH agonist). After 8 cycles patients will continue hormonal therapy.